100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44DC016246
Award Date
4/6/17
Completion Date
3/31/21
Dollars Obligated
$1.5M
Overview
Activity
5
Transactions
5
Subawards
Similar Awards
Federal Agency
National Institute on Deafness and Other Communincation Disorders
Awardee
Iotamotion, Inc. (HVTWTNGRTV88)
Federal Grant Program
93.173
Assistance Type
Project Grant
Place of Performance
Iowa City, IA, USA
Update #1
Update #2
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS
Posted 4/5/17
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS - ABSTRACT: SINCE THEIR CLINICAL INTRODUCTION OVER 30 YEARS AGO, COCHLEAR IMPLANTS (CIS) HAVE HAD A REMARKABLE IMPACT ON PATIENTS EXPERIENCING MODERATE-TO-PROFOUND HEARING LOSS. RECENT ADVANCES IN TECHNOLOGY HAVE DRIVEN THE DEVELOPMENT OF "HEARING PRESERVATION" IMPLANTS AND PROCEDURES DESIGNED TO PRESERVE THE RESIDUAL ACOUSTIC HEARING OF PATIENTS WHILE TREATING THE DAMAGED AREAS OF THE EAR WITH AN ELECTRICALLY STIMULATED CI. DESPITE THESE ADVANCES, OVER HALF OF PATIENTS UNDERGOING THIS PROCEDURE WILL EVENTUALLY LOSE RESIDUAL HEARING MONTHS TO YEARS AFTER SURGERY LIKELY DUE TO COCHLEAR TRAUMA SUSTAINED DURING THE SURGERY. ADDITIONALLY, BECAUSE CURRENT TECHNIQUES DO NOT ALLOW THE ELECTRODE TO BE INSERTED FARTHER INTO THE COCHLEA TO REACH NOW DYSFUNCTIONAL REGIONS, PATIENTS EITHER REQUIRE ADDITIONAL SURGERY OR LIVE WITH SUBOPTIMAL HEARING ONCE AGAIN. IOTAMOTION IS DEVELOPING AN IMPLANTABLE ROBOTIC-ASSISTED POSITIONING SYSTEM TO ENABLE PRECISE CONTROL OF INTRACOCHLEAR ELECTRODES BOTH INTRA- AND POST-OPERATIVELY TO REDUCE THE EFFECTS OF POST-SURGICAL HEARING LOSS. THE ANTICIPATED IMPACT OF THIS TECHNOLOGY WILL BE TO IMPROVE THE LONG-TERM OUTCOMES OF PATIENTS UNDERGOING "HEARING PRESERVATION" COCHLEAR IMPLANTATION AS WELL AS INCREASE THE CANDIDACY RANGE FOR THIS PROCEDURE. THE OVERALL GOAL OF THIS DIRECT-TO-PHASE II SBIR PROJECT IS TO FURTHER DEVELOP AND ULTIMATELY COMMERCIALIZE IOTAMOTION'S PROPRIETARY TECHNOLOGY. DURING "PHASE I-EQUIVALENT SBIR" STUDIES, IOTAMOTION DEVELOPED AND CHARACTERIZED AN INITIAL PROTOTYPE TO ESTABLISH PROOF OF CONCEPT AND FEASIBILITY IN CADAVERIC MODELS. FOLLOWING THAT SUCCESS, PHASE II WILL CONTINUE TO DEVELOP THE TECHNOLOGY TOWARD COMMERCIALIZATION WITH THE FOLLOWING SPECIFIC AIMS: 1) VERIFY DEVICE COMPATIBILITY AND "OPEN" PLATFORM WITH COMMERCIALLY AVAILABLE COCHLEAR IMPLANTS . USING 3 CLINICALLY AVAILABLE ELECTRODES, WE WILL ESTABLISH THE PROCEDURE, INSTRUCTIONS, AND EASE OF USE FOR INTEGRATING EACH ELECTRODE WITHIN THE DEVICE, THEN DETERMINE THE MAXIMUM STALL FORCE THAT CAN OCCUR WITH EACH DEVICE/ELECTRODE COMBINATION. 2) ESTABLISH THAT THE IOTAMOTION PILOT-LINE SYSTEM MEETS FUNCTIONAL, QUALITY, SAFETY, AND BIOCOMPATIBILITY REQUIREMENTS IN A GLP ENVIRONMENT. USING A COMBINATION OF INTERNATIONAL STANDARDS AND IN-HOUSE EXPERIMENTS, WE WILL DEMONSTRATE THAT THE DEVICE CAN BE STERILIZED, IS BIOCOMPATIBLE, AND CAN REMAIN FUNCTIONAL IN THE BODY FOR UP TO 6 MONTHS. QUALITY STANDARDS WILL BE IMPLEMENTED TO ENSURE VALID DATA ARE COLLECTED FOR EVENTUAL REGULATORY SUBMISSION. 3) EVALUATE THE EFFICACY OF THE IOTAMOTION ROBOTIC-ASSISTED SURGICAL SYSTEM IN A LONG-TERM LARGE-ANIMAL MODEL. PHASE II WILL CONCLUDE WITH AN EVALUATION OF THE DEVICE EFFICACY IN AN ESTABLISHED SHEEP MODEL OVER 3 MONTHS. COMPLETING THESE AIMS WILL SET THE STAGE FOR OUR SYSTEM DEVELOPMENT AND PRODUCTION IN A GMP ENVIRONMENT WITH PRIVATE-SECTOR PARTNERING AND EXECUTION OF A PROSPECTIVE CLINICAL TRIAL DESIGNED TO ESTABLISH SAFETY AND EFFICACY IN HUMANS. THE PHASE II PROJECT ENABLES IOTAMOTION TO ACHIEVE SIGNIFICANT COMMERCIALIZATION MILESTONES, DRIVING THE COMPANY FORWARD TOWARD IMPROVING THE HEARING AND QUALITY OF LIFE FOR MILLIONS WORLDWIDE.
$0
8/24/21
Not listed
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS - ABSTRACT: SINCE THEIR CLINICAL INTRODUCTION OVER 30 YEARS AGO, COCHLEAR IMPLANTS (CIS) HAVE HAD A REMARKABLE IMPACT ON PATIENTS EXPERIENCING MODERATE-TO-PROFOUND HEARING LOSS. RECENT ADVANCES IN TECHNOLOGY HAVE DRIVEN THE DEVELOPMENT OF "HEARING PRESERVATION" IMPLANTS AND PROCEDURES DESIGNED TO PRESERVE THE RESIDUAL ACOUSTIC HEARING OF PATIENTS WHILE TREATING THE DAMAGED AREAS OF THE EAR WITH AN ELECTRICALLY STIMULATED CI. DESPITE THESE ADVANCES, OVER HALF OF PATIENTS UNDERGOING THIS PROCEDURE WILL EVENTUALLY LOSE RESIDUAL HEARING MONTHS TO YEARS AFTER SURGERY LIKELY DUE TO COCHLEAR TRAUMA SUSTAINED DURING THE SURGERY. ADDITIONALLY, BECAUSE CURRENT TECHNIQUES DO NOT ALLOW THE ELECTRODE TO BE INSERTED FARTHER INTO THE COCHLEA TO REACH NOW DYSFUNCTIONAL REGIONS, PATIENTS EITHER REQUIRE ADDITIONAL SURGERY OR LIVE WITH SUBOPTIMAL HEARING ONCE AGAIN. IOTAMOTION IS DEVELOPING AN IMPLANTABLE ROBOTIC-ASSISTED POSITIONING SYSTEM TO ENABLE PRECISE CONTROL OF INTRACOCHLEAR ELECTRODES BOTH INTRA- AND POST-OPERATIVELY TO REDUCE THE EFFECTS OF POST-SURGICAL HEARING LOSS. THE ANTICIPATED IMPACT OF THIS TECHNOLOGY WILL BE TO IMPROVE THE LONG-TERM OUTCOMES OF PATIENTS UNDERGOING "HEARING PRESERVATION" COCHLEAR IMPLANTATION AS WELL AS INCREASE THE CANDIDACY RANGE FOR THIS PROCEDURE. THE OVERALL GOAL OF THIS DIRECT-TO-PHASE II SBIR PROJECT IS TO FURTHER DEVELOP AND ULTIMATELY COMMERCIALIZE IOTAMOTION'S PROPRIETARY TECHNOLOGY. DURING "PHASE I-EQUIVALENT SBIR" STUDIES, IOTAMOTION DEVELOPED AND CHARACTERIZED AN INITIAL PROTOTYPE TO ESTABLISH PROOF OF CONCEPT AND FEASIBILITY IN CADAVERIC MODELS. FOLLOWING THAT SUCCESS, PHASE II WILL CONTINUE TO DEVELOP THE TECHNOLOGY TOWARD COMMERCIALIZATION WITH THE FOLLOWING SPECIFIC AIMS: 1) VERIFY DEVICE COMPATIBILITY AND "OPEN" PLATFORM WITH COMMERCIALLY AVAILABLE COCHLEAR IMPLANTS . USING 3 CLINICALLY AVAILABLE ELECTRODES, WE WILL ESTABLISH THE PROCEDURE, INSTRUCTIONS, AND EASE OF USE FOR INTEGRATING EACH ELECTRODE WITHIN THE DEVICE, THEN DETERMINE THE MAXIMUM STALL FORCE THAT CAN OCCUR WITH EACH DEVICE/ELECTRODE COMBINATION. 2) ESTABLISH THAT THE IOTAMOTION PILOT-LINE SYSTEM MEETS FUNCTIONAL, QUALITY, SAFETY, AND BIOCOMPATIBILITY REQUIREMENTS IN A GLP ENVIRONMENT. USING A COMBINATION OF INTERNATIONAL STANDARDS AND IN-HOUSE EXPERIMENTS, WE WILL DEMONSTRATE THAT THE DEVICE CAN BE STERILIZED, IS BIOCOMPATIBLE, AND CAN REMAIN FUNCTIONAL IN THE BODY FOR UP TO 6 MONTHS. QUALITY STANDARDS WILL BE IMPLEMENTED TO ENSURE VALID DATA ARE COLLECTED FOR EVENTUAL REGULATORY SUBMISSION. 3) EVALUATE THE EFFICACY OF THE IOTAMOTION ROBOTIC-ASSISTED SURGICAL SYSTEM IN A LONG-TERM LARGE-ANIMAL MODEL. PHASE II WILL CONCLUDE WITH AN EVALUATION OF THE DEVICE EFFICACY IN AN ESTABLISHED SHEEP MODEL OVER 3 MONTHS. COMPLETING THESE AIMS WILL SET THE STAGE FOR OUR SYSTEM DEVELOPMENT AND PRODUCTION IN A GMP ENVIRONMENT WITH PRIVATE-SECTOR PARTNERING AND EXECUTION OF A PROSPECTIVE CLINICAL TRIAL DESIGNED TO ESTABLISH SAFETY AND EFFICACY IN HUMANS. THE PHASE II PROJECT ENABLES IOTAMOTION TO ACHIEVE SIGNIFICANT COMMERCIALIZATION MILESTONES, DRIVING THE COMPANY FORWARD TOWARD IMPROVING THE HEARING AND QUALITY OF LIFE FOR MILLIONS WORLDWIDE.
$0
8/24/21
Not listed
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS
$0
3/4/20
Not listed
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS
$758.9k
4/11/18
Not listed
EVALUATION OF A ROBOTIC ASSISTED SURGICAL SYSTEM FOR HEARING LOSS
$709.6k
4/5/17